Although a recent consensus molecular analysis individuated the c-MYC alteration as a specific marker of a particular CRC sub-group (the CMS2 subtype), definitively confirming the involvement of c-MYC in the CRC pathogenesis, the same study did not find a significant association of this group to a better or worse OS or PFS [23,24]. This evidence concerns the gene MYC and colorectal carcinoma.